Eloxx Q2 2026 net loss $4.5M; cash $62M; exaluren Phase 2b to start Q3 2026

Eloxx Pharmaceuticals, Inc.

2026-Q2 EPS reported -$1.48

Net loss of $4.5M ($0.39/share) for Q2 2026 vs $1.9M ($5.45/share) in Q2 2025; R&D spend up to $2.8M.
Completed $66M public offering (2.975M shares at $11.00) plus pre-funded warrants; net proceeds $58.3M.
Cash and equivalents $62.0M as of June 30, 2026; no debt; expected to fund into mid-2028.
Phase 2b trial of exaluren in Alport syndrome expected to start Q3 2026; topline data mid-2027.
EU granted orphan designation for exaluren in ADPKD; Phase 2 trial planned 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.